How many drugs treat Lymphangiomatosis?

Drug Landscape tracks 3 marketed treatments for Lymphangiomatosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/lymphangiomatosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lymphangiomatosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lymphangiomatosis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Lymphangiomatosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rapamune	sirolimus	Pfizer	mTOR Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein kinase mTOR	1999-01-01
Rapamune	Rapamune	Wyeth is now a wholly owned subsidiary of Pfizer		Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2
Rapamycin	Rapamycin	Institut National de la Santé Et de la Recherche Médicale, France		Peptidyl-prolyl cis-trans isomerase FKBP3, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Institut National de la Santé Et de la Recherche Médicale, France · 1 drug in Lymphangiomatosis
Pfizer · 1 drug in Lymphangiomatosis
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in Lymphangiomatosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Lymphangiomatosis:

Cite this brief

Drug Landscape (2026). Lymphangiomatosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lymphangiomatosis. Accessed 2026-06-10.

Lymphangiomatosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing